Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q3

2160.TEDINET S100SA1Y
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥20.5bn2023-01-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥6.5bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥17.4bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥12.8bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥4.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥6.8bn2023-01-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥1.3bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥1.5bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥490m2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥6.4bn2023-01-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.3bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥768m2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.2bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥433m2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥2.2bn2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥554m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥389m2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.1bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥400m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥4.8bn2023-01-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥790m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income−¥868m2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥324m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥126m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥48.5bnat 2023-09-30Cons.Assets IFRS
Total assets¥33.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥36.5bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥21.9bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥14.1bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥26.6bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥22.0bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥24.2bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥21.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥22.9bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥18.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥12.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥4.4bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥393m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥163m2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥3.7bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥4.1bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥5.0bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥646m2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥299m2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥46.612023-01-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.682023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥8.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥22.672022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥8.422022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥46.132023-01-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.332023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.112022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥22.462022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio50.0%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.8%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.8%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-09-30−¥24m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-09-30−¥24m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-09-30¥2.3bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-09-30¥2.3bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-09-30¥24m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-09-30¥888m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-09-30¥18.3bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-09-30¥18.3bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-09-30¥5.9bn
—segment totalrevenue2023-01-01 → 2023-09-30¥20.6bn
—segment totalrevenue external2023-01-01 → 2023-09-30¥20.5bn
—segment totalrevenue intersegment2023-01-01 → 2023-09-30¥24m
—segment totalsegment profit2023-01-01 → 2023-09-30¥6.8bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥38m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-09-30¥1.8bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-09-30¥1.7bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-09-30¥699m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-09-30¥796m
—segment totalrevenue2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥38m
—segment totalsegment profit2022-01-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 682
ItemContextValueUnit
Equity IFRSPrior1YearInstant_OtherComponentsOfEquityIFRSMember3147631000JPY
Profit loss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember2213274000JPY
Profit loss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Profit loss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Other comprehensive income IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember1694595000JPY
Other comprehensive income IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember1694595000JPY
Comprehensive income IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_RetainedEarningsIFRSMember2213274000JPY
Comprehensive income IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Comprehensive income IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember1694595000JPY
Comprehensive income IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember1694595000JPY
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember-751883000JPY
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember－JPY
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember-19903000JPY
Changes in ownership interest in subsidiaries ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-19903000JPY
Issuance of new shares ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember19171000JPY
Issuance of new shares ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember19171000JPY
Issuance of new shares ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Issuance of new shares ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Issuance of new shares ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember-176000JPY
Issuance of new shares ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Issuance of new shares ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember-176000JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember5127000JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Issuance of share acquisition rights ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember5127000JPY
Share based payment transactions ss IFRSCurrentYTDDuration_ShareCapitalIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_CapitalSurplusIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_TreasurySharesIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_RetainedEarningsIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_ShareAcquisitionRightsIFRSMember106374000JPY
Share based payment transactions ss IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Share based payment transactions ss IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember106374000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass